Pirtobrutinib Versus Ibrutinib for Treating CLL
February 17, 2026
In the first head-to-head comparison, patients with CLL who were treated with either pirtobrutinib or ibrutinib responded equally well to both treatments.
In the first head-to-head comparison, patients with CLL who were treated with either pirtobrutinib or ibrutinib responded equally well to both treatments.
Patients with CLL who were treated with fixed duration ibrutinib plus venetoclax had a life expectancy that was similar to that of the general population.
MRD-guided treatment with ibrutinib plus venetoclax significantly improved quality of life for patients with relapsed / refractory CLL.
Combination liso-cel and ibrutinib produced deep remissions with undetectable MRD in most patients with relapsed / refractory CLL / SLL.
MRD-guided ibrutinib plus venetoclax is a very effective combination therapy for treating CLL, and it can provide durable responses.
Patients with CLL treated with ibrutinib have a 9-year overall survival rate, irrespective of high-risk features.
Treatment with ibrutinib-venetoclax produced high rates of uMRD and durable progression-free survival in patients with CLL irrespective of lymph node size.
Combination ibrutinib-venetoclax-obinutuzumab provided short-term control for patients with Richter’s transformation, but responses were not durable.
Ibrutinib may be taken alone or in combination with another medication as an initial (first-line) treatment.